Prognosis of hip osteonecrosis after cell therapy with a calculator and artificial intelligence: ten year collapse-free survival prediction on three thousand and twenty one hips
- PMID: 37036496
- DOI: 10.1007/s00264-023-05788-9
Prognosis of hip osteonecrosis after cell therapy with a calculator and artificial intelligence: ten year collapse-free survival prediction on three thousand and twenty one hips
Abstract
Purpose: Several reports have identified prognostic factors for hip osteonecrosis treated with cell therapy, but no study investigated the accuracy of artificial intelligence method such as machine learning and artificial neural network (ANN) to predict the efficiency of the treatment. We determined the benefit of cell therapy compared with core decompression or natural evolution, and developed machine-learning algorithms for predicting ten year collapse-free survival in hip osteonecrosis treated with cell therapy. Using the best algorithm, we propose a calculator for "prognosis hip osteonecrosis cell therapy (PHOCT)" accessible for clinical use.
Methods: A total of 3145 patients with 5261 osteonecroses without collapses were included in this study, comprising 1321 (42%) men and 1824 (58%) women, with a median age of 34 (12-62) years. Cell therapy was the treatment for 3021 hips, core decompression alone for 1374 hips, while absence of treatment was the control group of 764 hips. First, logistic regression and binary logistic regression analysis were performed to compare results of the three groups at ten years. Then an artificial neural network model was developed for ten year collapse-free survival after cell therapy. The models' performances were compared. The algorithms were assessed by calibration, and performance, and with c-statistic as measure of discrimination. It ranges from 0.5 to 1.0, with 1.0 being perfect discrimination and 0.5 poor (no better than chance at making a prediction).
Results: Among the 3021 hips with cell therapy, 1964 hips (65%) were collapse-free survival at ten years, versus 453 (33%) among those 1374 treated with core decompression alone, and versus 115 (15%) among 764 hips with natural evolution. We analyzed factors influencing the prediction of collapse-free period with classical statistics and artificial intelligence among hips with cell therapy. After selecting variables, a machine learning algorithm created a prognosis osteonecrosis cell therapy calculator (POCT). This calculator proved to have good accuracy on validation in these series of 3021 hip osteonecroses treated with cell therapy. The algorithm had a c-statistic of 0.871 suggesting good-to-excellent discrimination when all the osteonecroses were mixed. The c-statistics were calculated separately for subpopulations of categorical osteonecroses. It retained good accuracy, but underestimated ten year survival in some subgroups, suggesting that specific calculators could be useful for some subgroups. This study highlights the importance of multimodal evaluation of patient parameters and shows the degree to which the outcome is modified by some decisions that are within a surgeon's control, as the number of cells to aspirate, the choice of injecting in both the osteonecrosis and the healthy bone, the choice between unilateral or bilateral injection, and the possibility to do a repeat injection.
Conclusion: Many disease conditions and the heterogeneities of patients are causes of variation of outcome after cell therapy for osteonecrosis. Predicting therapeutic effectiveness with a calculator allows a good discrimination to target patients who are most likely to benefit from this intervention.
Keywords: Artificial intelligence; Cell therapy; Collapse; Collapse-free period; Hip osteonecrosis; Machine learning; Mesenchymal stem cells; Neural networks and deep learning.
© 2023. The Author(s) under exclusive licence to SICOT aisbl.
Similar articles
-
Revisiting prediction of collapse in hip osteonecrosis with artificial intelligence and machine learning: a new approach for quantifying and ranking the contribution and association of factors for collapse.Int Orthop. 2023 Mar;47(3):677-689. doi: 10.1007/s00264-022-05631-7. Epub 2022 Nov 14. Int Orthop. 2023. PMID: 36374346
-
Stem Cells Combined With Platelet-rich Plasma Effectively Treat Corticosteroid-induced Osteonecrosis of the Hip: A Prospective Study.Clin Orthop Relat Res. 2018 Feb;476(2):388-397. doi: 10.1007/s11999.0000000000000033. Clin Orthop Relat Res. 2018. PMID: 29529674 Free PMC article.
-
Cell therapy versus simultaneous contralateral decompression in symptomatic corticosteroid osteonecrosis: a thirty year follow-up prospective randomized study of one hundred and twenty five adult patients.Int Orthop. 2018 Jul;42(7):1639-1649. doi: 10.1007/s00264-018-3941-8. Epub 2018 May 9. Int Orthop. 2018. PMID: 29744647 Clinical Trial.
-
Hip arthroplasty dislocation risk calculator: evaluation of one million primary implants and twenty-five thousand dislocations with deep learning artificial intelligence in a systematic review of reviews.Int Orthop. 2023 Feb;47(2):557-571. doi: 10.1007/s00264-022-05644-2. Epub 2022 Nov 29. Int Orthop. 2023. PMID: 36445413
-
Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique.J Bone Joint Surg Am. 2005 Mar;87 Suppl 1(Pt 1):106-12. doi: 10.2106/JBJS.D.02662. J Bone Joint Surg Am. 2005. PMID: 15743852 Review.
Cited by
-
Acetabular coverage exerts minimal influence on femoral head collapse and the necessity for surgical intervention in patients with osteonecrosis of femoral head.Int Orthop. 2024 Sep;48(9):2331-2337. doi: 10.1007/s00264-024-06238-w. Epub 2024 Jun 20. Int Orthop. 2024. PMID: 38898160 Free PMC article.
-
The use of extracorporeal shock wave therapy (ESWT) in treating osteonecrosis of the femoral head (AVNFH): a retrospective study.Int Orthop. 2023 Dec;47(12):2953-2960. doi: 10.1007/s00264-023-05904-9. Epub 2023 Jul 27. Int Orthop. 2023. PMID: 37498339
-
Factors related to collapse progression in Japanese Investigation Committee classification type B osteonecrosis of the femoral head.Int Orthop. 2024 Aug;48(8):2033-2040. doi: 10.1007/s00264-024-06221-5. Epub 2024 May 28. Int Orthop. 2024. PMID: 38806819
-
Evaluation of the long-term patient-reported outcomes after hip arthroplasty or joint preserving with Sugioka femoral osteotomy in patients with femoral head osteonecrosis.Int Orthop. 2024 May;48(5):1201-1208. doi: 10.1007/s00264-024-06118-3. Epub 2024 Feb 20. Int Orthop. 2024. PMID: 38376531 Free PMC article.
-
Mesenchymal Stem Cell Therapy for Bone Repair of Human Hip Osteonecrosis with Bilateral Match-Control Evaluation: Impact of Tissue Source, Cell Count, Disease Stage, and Volume Size on 908 Hips.Cells. 2024 May 1;13(9):776. doi: 10.3390/cells13090776. Cells. 2024. PMID: 38727312 Free PMC article.
References
-
- Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H, Flouzat-Lachaniette CH (2016) Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress. Clin Orthop Surg 8(1):1–8. https://doi.org/10.4055/cios.2016.8.1.1 - DOI - PubMed - PMC
-
- Hernigou P, Beaujean F (2002) Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 405:14–23. https://doi.org/10.1097/00003086-200212000-00003 - DOI
-
- Gangji V, Hauzeur JP, Matos C et al (2004) Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J BoneJoint Surg Am 86–A:1153–60 - DOI
-
- Li J, Su P, Li J, Chen G, Xiong Y (2021) Efficacy and safety of stem cell combination therapy for osteonecrosis of the femoral head: a systematic review and meta-analysis. J Healthc Eng 2021:9313201. https://doi.org/10.1155/2021/9313201 . (eCollection 2021) - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources
Medical